低级别胶质瘤患者来源类器官模型的建立
本研究利用生理性5%氧合条件开发优化方案,从低级别胶质瘤原发组织建立类器官,成功率达91%(n=20/22),WHO 1-3级肿瘤成功率为87%(13/15),类器官保留了亲本肿瘤的干性、增殖、肿瘤-基质组成、细胞结构、突变及代谢特征,并可在体外维持数周至数月及生物库冻存后复苏。
要点
- 低级别胶质瘤类器官建立成功率为91%(n=20/22),WHO 1-3级肿瘤为87%(13/15)。
- 患者来源类器官可再现亲本肿瘤的干性、增殖及肿瘤-基质组成特征。
- 类器官在体外可维持数周至数月,生物库冻存后复苏不丢失完整性。
核心结论
- 报告了一种高效制备低级别胶质瘤忠实体外模型的方法,该平台有望支持该病的临床前研究。
研究设计与样本
- 利用生理性(5%)氧合条件开发优化方案,从低级别胶质瘤原发组织样本建立类器官。
- 采用代谢、基因组、组织学和谱系标记基因表达检测评估类器官的保真性。
- 样本来自胶质瘤各组织学亚型和肿瘤级别(WHO 1-4级),总成功率为91%(n=20/22),WHO 1-3级肿瘤成功率为87%(13/15)。
主要发现
- 患者来源类器官再现了各自亲本肿瘤标本的干性、增殖和肿瘤-基质组成特征。
- 亲本肿瘤的细胞结构、突变和代谢特征也得以保留。
- 低级别胶质瘤类器官在体外维持数周至数月,生物库冻存后复苏不丢失完整性。
临床怎么用
- 作者认为,通过该方法生成的新实验平台有望支持该病的临床前研究,尤其涉及肿瘤免疫学、肿瘤-基质相互作用、新药靶点识别及治疗反应谱个体化评估的研究。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Historically, creating patient-derived models of lower-grade glioma (LGG) has been challenging, contributing to few experimental platforms that support laboratory-based investigations of this disease. Although organoid modeling approaches have recently been employed to create in vitro models of high-grade glioma (HGG), it is unknown whether this approach can be successfully applied to LGG. METHODS: In this study, we developed an optimized protocol for the establishment of organoids from LGG primary tissue samples by utilizing physiologic (5%) oxygenation conditions and employed it to produce the first known suite of these models. To assess their fidelity, we surveyed key biological features of patient-derived organoids using metabolic, genomic, histologic, and lineage marker gene expression assays. RESULTS: Organoid models were created with a success rate of 91% (n = 20/22) from primary tumor samples across glioma histological subtypes and tumor grades (WHO Grades 1-4), and a success rate of 87% (13/15) for WHO Grade 1-3 tumors. Patient-derived organoids recapitulated stemness, proliferative, and tumor-stromal composition profiles of their respective parental tumor specimens. Cytoarchitectural, mutational, and metabolic traits of parental tumors were also conserved. Importantly, LGG organoids were maintained in vitro for weeks to months and reanimated after biobanking without loss of integrity. CONCLUSIONS: We report an efficient method for producing faithful in vitro models of LGG. New experimental platforms generated through this approach are well positioned to support preclinical studies of this disease, particularly those related to tumor immunology, tumor-stroma interactions, identification of novel drug targets, and personalized assessments of treatment response profiles.
引用
- Abdullah KG, Bird CE, Buehler JD, et al. Establishment of patient-derived organoid models of lower-grade glioma. Neuro Oncol. 2022. PMID: 34850183. doi:10.1093/neuonc/noab273
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。